Beiying Dai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beiying Dai has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Yong Yang
Center for New Drug Safety Evaluation and Research, State Key Laboratory of Natural Medicines, China Pharmaceutical University, China
25 shared publications - Xinghua Gao
Institute of Translational Medicine China Pharmaceutical University Nanjing Jiangsu China
24 shared publications - Anqi Chen
Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, P.R. China
23 shared publications - Chongxiu Yue
Center for New Drug Safety Evaluation and Research, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, P.R. China
23 shared publications - Dongquan Jing
Institute of Translational Medicine China Pharmaceutical University Nanjing Jiangsu China
23 shared publications - Huijuan Da
Institute of Translational Medicine China Pharmaceutical University Nanjing Jiangsu China
23 shared publications
Latest Publications
- 11 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Beta-1,3-glucuronosyltransferase (B3GAT3) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis, serving as a desirable anti-HCC target. Based on our micromolar lead TMLB-C16 (IC50 = 6.22−6.53 μM, KD = 3.96 μM), 60 novel derivatives were designed via systematic structure−activity relationship optimization. The optimized candidate TMLB-G9 is the first nanomolar B3GAT3 inhibitor bearing a 6-methoxyquinoline-4-carboxamide scaffold. It exhibits stronger B3GAT3 binding affinity (KD = 0.72 μM) than both TMLB-C16 and natural substrate UDP-GlcUA (KD = 1.32 μM). TMLB-G9 exhibits potent antiproliferative activity against Huh7 and Hep3B cells (IC50 = 0.31−0.36 μM) and broad-spectrum antitumor efficacy. It suppresses HCC colony formation, migration, and invasion, while inducing G0/G1 arrest and apoptosis. With good in vivo tolerance and safety, TMLB-G9 exhibited superior anti-HCC activity to TMLB-C16 in two HCC xenograft models. In conclusion, TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy.
- 11 September 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Structure-Guided Design, Synthesis, and Evaluation of Novel 6-Methoxyquinoline-4-carboxamide Derivatives as First-in-Class Nano-Molar B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Beta-1,3-glucuronosyltransferase (B3GAT3) is overexpressed in hepatocellular carcinoma (HCC) and correlates with poor prognosis, serving as a desirable anti-HCC target. Based on our micromolar lead TMLB-C16 (IC50 = 6.22−6.53 μM, KD = 3.96 μM), 60 novel derivatives were designed via systematic structure−activity relationship optimization. The optimized candidate TMLB-G9 is the first nanomolar B3GAT3 inhibitor bearing a 6-methoxyquinoline-4-carboxamide scaffold. It exhibits stronger B3GAT3 binding affinity (KD = 0.72 μM) than both TMLB-C16 and natural substrate UDP-GlcUA (KD = 1.32 μM). TMLB-G9 exhibits potent antiproliferative activity against Huh7 and Hep3B cells (IC50 = 0.31−0.36 μM) and broad-spectrum antitumor efficacy. It suppresses HCC colony formation, migration, and invasion, while inducing G0/G1 arrest and apoptosis. With good in vivo tolerance and safety, TMLB-G9 exhibited superior anti-HCC activity to TMLB-C16 in two HCC xenograft models. In conclusion, TMLB-G9 is a promising B3GAT3 inhibitor worthy of further development for HCC therapy.
- 6 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 303, 118471
Discovery of novel small molecule inhibitor targeting the tumor promoting effect of transcription factor PLAGL2
- 6 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 303, 118471
Discovery of novel small molecule inhibitor targeting the tumor promoting effect of transcription factor PLAGL2
- 26 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 10743-10773
Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Beta-1,3-glucuronosyltransferase (B3GAT3), overexpressed in hepatocellular carcinoma (HCC) and negatively correlated to prognosis, is a promising target for cancer therapy. Currently, no studies have reported small molecule inhibitors of B3GAT3. In this study, we designed and synthesized a series of small-molecule inhibitors of B3GAT3 through virtual screening and structure optimization. The lead compound TMLB-C16 exhibited potent B3GAT3 inhibitory activity (KD = 3.962 mu M) by effectively suppressing proliferation and migration, and inducing cell cycle arrest and apoptosis in MHCC-97H (IC50= 6.53 +/- 0.18 mu M) and HCCLM3 (IC50= 6.22 +/- 0.23 mu M) cells. Furthermore, compound TMLB-C16 demonstrated favorable pharmacokinetic properties with a relatively high bioavailability of 68.37%. It significantly inhibited tumor growth in both MHCC-97H and HCCLM3 xenograft tumor models without causing obvious toxicity. These results indicate that compound TMLB-C16 is an effective small molecule inhibitor of B3GAT3, providing a basis for the future development of B3GAT3-targeted drugs.
- 26 June 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (13) , 10743-10773
Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma
Beta-1,3-glucuronosyltransferase (B3GAT3), overexpressed in hepatocellular carcinoma (HCC) and negatively correlated to prognosis, is a promising target for cancer therapy. Currently, no studies have reported small molecule inhibitors of B3GAT3. In this study, we designed and synthesized a series of small-molecule inhibitors of B3GAT3 through virtual screening and structure optimization. The lead compound TMLB-C16 exhibited potent B3GAT3 inhibitory activity (KD = 3.962 mu M) by effectively suppressing proliferation and migration, and inducing cell cycle arrest and apoptosis in MHCC-97H (IC50= 6.53 +/- 0.18 mu M) and HCCLM3 (IC50= 6.22 +/- 0.23 mu M) cells. Furthermore, compound TMLB-C16 demonstrated favorable pharmacokinetic properties with a relatively high bioavailability of 68.37%. It significantly inhibited tumor growth in both MHCC-97H and HCCLM3 xenograft tumor models without causing obvious toxicity. These results indicate that compound TMLB-C16 is an effective small molecule inhibitor of B3GAT3, providing a basis for the future development of B3GAT3-targeted drugs.